Knopp Biosciences, a drug discovery and development company, announced positive results from its Phase 2 Exhale trial of dexpramipexole, demonstrating that oral medication improves airflow obstruction in asthma as measured by forced expiratory volume (FEV1), largely through its effect on forced vital capacity (FVC). The data, presented at the American Academy of Allergy Asthma & Immunology annual meeting, showed that reductions in blood and tissue eosinophils by dexpramipexole are associated with improved lung health. The company revealed that 97 percent of dexpramipexole-treated patients completed the primary assessment phase with no serious adverse events and no adverse events leading to discontinuation. The company expects that it will be rapidly moving into Phase 3 trials.  

Source: finance.yahoo.com